Abstract: Objective：To systematically review the influence of CYP2C19 genetic polymorphisms on levofloxacin-containing therapy on eradication rates of Helicobacter pylori（HP） infection. Methods： Such databases as PubMed， Embase， CBM， CNKI， Wanfang Data and CQVIP were electronically searched for clinical studies on CYP2C19 genetic polymorphisms and levofloxacinand Helicobacter pylori. According to the inclusion and exclusion criteria， literatures were screened， and data were extracted， and the methodologically quality of included studies were also examined. Meta-analysis were then performed using RevMan 5.3 and Stata 13.1 softwares. Results： A total of 7 studies involving 846 subjects were included. The results of Meta-analysis showed that CYP2C19 genotype status influences levofloxacin-containing triple therapy(proton pump inhibitors and amoxicillin and levofloxacin)： eradication rates for Helicobacter pylori in extensive metabolizer(EM) and intermediate metabolizer(IM) phenotypes were slightly lower than in poor metabolizer(PM) phenotype [EM vs PM：78.4% vs 91.7%， OR=0.38， 95%CI(0.18， 0.79)；IM vs PM：83.7% vs 91.7%， OR=0.43， 95%CI(0.20， 0.92)，P<0.05]， respectively. Further analysis demonstrated omeprazole may cause the difference above. CYP2C19 genetic polymorphism did not influencetotal eradication rates of Helicobacter pylori in the regiment of levofloxacin-containing bismuth quadruple therapy(P>0.05). Conclusion： CYP2C19 genetic polymorphism might affect the efficacy of omeprazole， amoxicillin and levofloxacin triple therapy but did not affect levofloxacin-containing bismuth quadruple therapy to the eradication rates of Helicobacter pylori infection， therefore CYP2C19 genetic polymorphism tests were not required if levofloxacin-containing bismuth quadruple therapy was chosen as eradication treatment.